Skip to main content

Advertisement

Table 1 Demographic and clinical and laboratory results

From: Machine learning to predict rapid progression of carotid atherosclerosis in patients with impaired glucose tolerance

  All Rapid progressors Non-rapid progressors p value
(n = 382) (n = 39) (n = 343)
Age (years) 53.6 ± 0.6 54.1 ± 1.6 53.5 ± 0.6 NS
Female gender (%) 54.19 64.10 53.06 NS
Hispanic race (%)* 31.15 15.38 32.94 0.039
Enrollment site* 382 39 343 <0.001
 Site 1 80 5 75
 Site 2 46 15 31
 Site 3 54 1 53
 Site 4 46 7 39
 Site 5 45 8 37
 Site 6 83 3 80
 Site 7 28 0 28
Hypertension (%) 248 (64.9 %) 21 (53.8 %) 227 (66.2 %) NS
On lipid lowering therapy (%) 123 (32.4 %) 9 (23.1 %) 114 (33.4 %) NS
Known vascular disease (%) 7 (1.8 %) 0 (0 %) 7 (2.0 %) NS
Weight (kg) 92.8 ± 0.9 90.1 ± 2.6 93.1 ± 0.9 NS
Mean arterial pressure (mmHg) 90.7 ± 0.6 90.9 ± 1.6 90.7 ± 0.6 NS
HbA1c (%) 5.48 ± 0.02 5.37 ± 0.05 5.50 ± 0.02 NS
Plasma creatinine* 0.74 ± 0.02 0.87 ± 0.3 0.72 ± 0.03 0.025
Urine mean microalbumin* 14.6 ± 1.0 11.0 ± 2.7 15.0 ± 1.1 0.019
PAI-1* 15.2 ± 0.5 14.7 ± 3.1 15.2 ± 0.4 0.02
Pioglitazone treatment (%) 49.21 46.15 49.56 NS
Baseline CIMT (μM) 759 ± 8 750 ± 29 760 ± 08 NS
Change in CIMT (μM)* 11.1 ± 25.9 58.0 ± 17.5 5.8 ± 17.5 <0.001
  1. *p < 0.05; NS- not significant, HbA1c- glycated hemoglobin, PAI-1-plasminogen activator inhibitor-1, CIMT-carotid intima-media thickness